PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Otava Ltd Introduces New 11beta-hydroxysteroid Dehydrogenase Type 1 Target-focused Library - OTAVA Ltd offers new 11beta-hydroxysteroid dehydrogenase type 1 target-focused library containing 1,060 compounds which has been designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human 11
Otava Ltd Introduces New 11beta-hydroxysteroid Dehydrogenase Type 1 Target-focused Library

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2014/11/14 - OTAVA Ltd offers new 11beta-hydroxysteroid dehydrogenase type 1 target-focused library containing 1,060 compounds which has been designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human 11.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, 11beta-HSD1) is an NADPH-dependent enzyme, which catalyses conversion of inactive glucocorticoids 11-dehydrocorticosterone and cortisone to active corticosterone and cortisol and vice versa. 11beta-HSD1 is also implicated in the regulation of glucocorticoid access to nuclear receptors.

Chronically increased levels of glucocorticoids are associated with the development of obesity, diabetes, cardiovascular disease (the metabolic syndrome) and impairments in memory. Dysregulation of 11beta-HSD1 has been reported to be involved in all of these human pathologies. It was demonstrated that the inhibition of 11beta-HSD1 activity decreased hypertension, insulin resistance, glucose intolerance, and hypertriglyceridemia. Therefore, 11beta-HSD1 is an attractive drug target for the treatment of the metabolic syndrome and cognitive impairment.
OTAVA Ltd. offers new 11beta-hydroxysteroid dehydrogenase type 1 target-focused library containing 1,060 compounds which has been designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human 11beta-HSD1 (PDB ID: 4C7K) and filtering by score values and hydrogen bonds formed between ligand and key residues of the 11beta-HSD1 active site. The library comprises drug-like compounds only.

The 11beta-HSD1 focused library from OTAVA is an excellent choice for drug discovery in endocrine and metabolic disorders treatment.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Otava Ltd Introduces New 11beta-hydroxysteroid Dehydrogenase Type 1 Target-focused Library

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Andriy Petrenko - OtavaChemicals.com 
416-549-8030 info[.]otavachemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)